Cystic fibrosis (CF) is a genetic disorder characterized by the accumulation of thick, sticky mucus in the lungs and other organs. Current treatment options focus on managing symptoms, but there is a need for therapies that modify the underlying disease process. The Signal Transducer and Activator of Transcription 3 (STAT3) and Notch signaling pathways have been implicated in CF pathogenesis. Activation of STAT3 contributes to chronic inflammation and tissue damage, while Notch signaling promotes fibrosis and fibroproliferative diseases. Niclosamide, an anthelmintic drug, has shown inhibitory effects on these pathways but has limited clinical utility. Lipid-Drug Conjugate nanoparticles (LDCs) offer a promising drug delivery system for enhancing the bioavailability and targeting of therapeutic compounds. In this study, we propose the preparation of Niclosamide LDCs (Niclo-LDCs) using Octadecylamine as a lipid. We hypothesize that Niclo-LDCs have the potential to inhibit Notch and STAT3 activation, thereby reducing inflammation in the lungs of CF patients. By specifically targeting the cross talk between these pathways, Niclo-LDCs may represent a promising therapeutic strategy for CF treatment. Further investigation and validation of this hypothesis could lead to the development of novel treatments for CF that modify the underlying disease process.